Menu Search
Equities

Interpace Biosciences Inc

PF42:MUN

Interpace Biosciences Inc

Actions
  • Price (EUR)2.88
  • Today's Change-0.02 / -0.69%
  • Shares traded100.00
  • 1 Year change+179.61%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.

  • Revenue in USD (TTM)44.89m
  • Net income in USD4.89m
  • Incorporated1998
  • Employees108.00
  • Location
    Interpace Biosciences IncWaterview PlazaSuite 310, 2001 Route 46PARSIPPANY 07054United StatesUSA
  • Phone+1 (412) 224-6100
  • Fax+1 (302) 636-5454
  • Websitehttps://www.interpace.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.